Summary:
- Neurocrine Biosciences, a leading biopharmaceutical company, has presented positive data from a Phase 2 study of a new drug candidate.
- The drug, known as NBI-921352, is being developed to treat a rare and severe form of epilepsy called SCN8A-related epilepsy.
- The study results show that NBI-921352 was effective in reducing seizure frequency and improving the overall condition of patients, paving the way for further clinical trials and potential approval.